The MAPKAPK5 Knockout Raji Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population designed for targeted disruption of the MAPKAPK5 gene in a human B lymphocyte background, providing a heterogeneous loss-of-function model that avoids clonal selection bias. The knockout is generated using CRISPR/Cas9-mediated gene disruption, resulting in a mixed population of cells with impaired MAPKAPK5 expression. This format is particularly suited for high-throughput screening and bulk functional assays where clonal variation may confound results.
The host cell line, Raji, is an Epstein-Barr virus (EBV)-positive B lymphocyte line derived from a Burkitt lymphoma patient. These cells exhibit characteristic features of aggressive B-cell lymphoma, including rapid proliferation, resistance to apoptosis, and expression of surface markers such as CD19 and CD20. As a widely adopted model for B-cell malignancies, Raji cells are instrumental for studying lymphomagenesis, immune evasion, and the molecular underpinnings of hematopoietic cancers. Their EBV-positive status further provides a context for investigating virus-host interactions and viral oncogenesis.
MAPKAPK5 encodes a serine/threonine kinase that functions as a critical node in stress and mitogenic signal transduction. The kinase is activated upstream by the p38 MAPK family members MAPK14 (p38??), MAPK11 (p38??), MAPK12 (p38??), and MAPK13 (p38??) in response to cytokines such as IL-1 and TNF, as well as by the atypical MAPKs MAPK6 (ERK3) and MAPK4 (ERK4) through direct complex formation. Once activated, MAPKAPK5 phosphorylates downstream effectors including HSPB1 (HSP27), CREB1, FOXO3, and c-FOS, thereby modulating transcriptional programs, apoptosis, and cell cycle progression. The kinase interacts with closely related family members MAPKAPK2 and MAPKAPK3, contributing to coordinated cellular responses to environmental cues.
In the context of Raji B lymphoma cells, MAPKAPK5 knockout provides a powerful tool to dissect the role of p38-MAPKAPK5 and ERK3/4-MAPKAPK5 signaling axes in malignant B-cell biology. Since aberrant MAPK signaling is implicated in lymphoma survival and chemoresistance, loss of this kinase may unmask either tumor-suppressive or oncogenic functions depending on the cellular milieu. The model enables researchers to evaluate how disruption of stress-activated kinase cascades influences lymphoma proliferation, apoptosis susceptibility, and gene expression signatures relevant to Burkitt lymphoma and other B-cell malignancies.
Typical research applications include examination of stress-induced apoptosis, kinase inhibitor profiling, and validation of MAPKAPK5 as a therapeutic target in lymphoma. The polyclonal population enables Western blotting for phosphorylated HSPB1 and CREB1, RT-qPCR for downstream targets, Annexin V/PI apoptosis detection, cell cycle analysis by flow cytometry, and viability assays. Phospho-p38 ELISA and kinase activity measurements can probe upstream signaling. These polyclonal knockout cells facilitate high-content screens for synthetic lethal interactions or resistance mechanisms. For technical inquiries, please contact Ascent Research.
